With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Do gender perceptions affect the way female physicians are treated in cardiology? Drs Melissa Walton-Shirley, Judith Hochman, Suzanne Oparil, and Lynne Warner Stevenson tackle this important question.
Studies suggest public smoking bans reduce the incidence of acute MI. So why is America not smoke-free? Dr Melissa Walton-Shirley discusses this important issue with the AHA's Nancy Brown and Dr Clyde Yancy.
Distinguished by a lifelong commitment to rigorous investigation, Dr Carl Pepine shares his life path and gives insight on tomorrow's cardiology leaders and why it may be increasingly difficult for medicine to keep attracting the best and brightest.
Join Drs Harrington and Blumenthal as they shine a light on real and perceived conflicts between researchers and industry in a discussion moderated by heartwire's Shelley Wood.
Join Dr Robert Califf for a thoughtful and timely interview with Dr Ray Gibbons on the core values he learned in his career in science and medicine and why they are imperative for physicians to keep in mind when contemplating the future of healthcare reform.
AHA president Dr Clyde Yancy and CEO Nancy Brown share insights from the recent sessions and discuss ongoing initiatives with heartwire's Shelley Wood.
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss important news from the Scientific Sessions and tackle the issue of too little, too soon in clinical trials today.
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
Dr Robert Califf sits down with Drs Alfred Bove, Jack Lewin, and Clyde Yancy and AHA CEO Nancy Brown to talk about the ACC and the AHA and their role in the debate on healthcare reform.
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.
Join Drs Valentin Fuster, William E Boden, and George D Dangas as they discuss the results, plus the evolution of therapy over the last forty years, the mechanisms of coronary artery disease progression in diabetic patients, and what is perhaps one of the most fundamental problems in the field: that patients today are still not treated to target with best medical therapy.
Join Dr Robert Califf for a probing and personal interview with Dr Steve Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
Dr Blumenthal talks to Drs Krumholz, Ridker, and Smith about how to approach target guidelines for LDL in the wake of JUPITER, SEARCH, and other lipid-lowering studies.
As theheart.org enters its 10th year join editor-in-chief, Dr Eric Topol, and his guests for a second look at the top news from the past decade. Throughout the coming months, we'll revisit the most important story from each of the last 10 years and ask: How has practice been affected? With time and perspective, what has changed and what have we learned?
How best to treat patients presenting with both coronary disease and diabetes? Join Drs Nesto and Fonseca on this rather slippery slope as they examine the data and provide practical guidance for treatment.
Join Drs Krumholz, Blumenthal, Harrington, Jessup, Ridker, Smith, Stone, Weintraub, and Yancy as they dissect the results of the JUPITER and debate the far-reaching clinical implications of this landmark study in Part 1 of the program. In Part 2, the panelists look at the positive sides of HF-Action and TIMACS and deliberate the real lessons learned from these negative trials.
Dr Melissa Walton-Shirley asks Drs Franz Messerli and Raymond Gibbons for their thoughts on dual RAAS inhibition and on what the future holds for ACE inhibitors and angiotensin-receptor blockers following ONTARGET and TRANSCEND.
Join Drs Valentin Fuster, William Boden, Antonio Colombo, Raymond Gibbons, Franz Messerli, Marc Pfeffer, Philip Poole-Wilson, Ph Gabriel Steg, Renu Virmani, and Harvey White as they plumb the depths of the SYNTAX (Part 1) and CARDIA trials and weigh in on the cancer scare in the SEAS study (Part 2).
Join heartwire's Larry Husten as he talks to Dr Harlan Krumholz and USA Today journalist Steve Sternberg about the decision to present the results of the ENHANCE trial at a unique opening session of the ACC 2008 Scientific Sessions, and about the response of the cardiology community and the media to the continuing controversy.
Join Drs Valentin Fuster, Robert Harrington, Steven Nissen, Gregg Stone, Clyde Yancy, Gilles Montalescot, Keith Fox, Frans Van de Werf, and Harlan Krumholz for an upfront and spirited discussion as they thrash out the controversies surrounding ENHANCE and STRADIVARIUS, consider the results of ONTARGET and PERISCOPE, and question the utility of surrogate end points.
Do current guidelines provide us with the direction for managing high-risk patients with dyslipidemia? Drs. Blumenthal, Ballantyne, and Ginsberg examine goals and strategies for managing patients at high risk.